Quick answer: High-trust sources include official FDA/CMS pages, provider websites, public review platforms, clinical labels, reputable news reports, and dated screenshots where available.
Policy areaStandard
CorrectionsFactual corrections should be reviewed and documented quickly.
Affiliate disclosureCommercial relationships must be disclosed before or near monetized CTAs.
Medical claimsContent must not replace clinician evaluation.

Plain-English summary

High-trust sources include official FDA/CMS pages, provider websites, public review platforms, clinical labels, reputable news reports, and dated screenshots where available. The safest editorial approach is to compare programs by price transparency, clinical oversight, pharmacy disclosure, refund/cancellation policy, support access, and whether the program is appropriate for the patient’s medical situation.

Key facts

QuestionAnswer
Core standardCompare GLP-1 programs using transparent prices, clinical oversight, pharmacy disclosure, and patient support.
Important limitationCompounded GLP-1 medications are not FDA-approved and may vary by state, pharmacy, formulation, and medical necessity.
Medical disclaimer: This page is for education and comparison. It is not medical advice. GLP-1 medications require evaluation by a licensed clinician. Compounded medications are not FDA-approved.

Sources and verification

  1. CMS Medicare GLP-1 Bridge
  2. CMS $50 monthly GLP-1 access announcement
  3. FDA compounded GLP-1 telehealth warning letters
  4. FDA 503B bulks proposal
  5. Reuters: employer GLP-1 coverage pullbacks
  6. NexLife official website
  7. NexLife: tirzepatide $129/mo month to month ($115 on 12 months), semaglutide $109 ($95), same price at every dose (as of Nov 6, 2026).